This project consists of financing expenditure on staff specifically recruited for the project and expenditure covering all other direct and indirect eligible costs of the project at a flat rate of 40 % of eligible staff expenditure. This is a collaborative project between Innopain, ANS Biotech, small R & D companies located in Saint Beauzire and Riom (63), SIGMA and Clermont Auvergne University. Pain has a major impact on quality of life and leads to neuropsychiatric disorders (sleep disorders, anxiety, depression, cognitive disorders...) in 70 % of patients. Societal and economic issues are also crucial as 60 % of people with chronic pain are less able or unable to work and 20 % report losing their jobs due to pain. Available drug treatments, almost all of which belong to older classes of compounds (opioids, NSAIDs, antidepressants, etc.), are ineffective and/or cause many adverse reactions. The objective of the OPTIM'DOL project is the design and development of new molecules, non-opioid antalgic, for the treatment of acute and chronic pain as well as the development of new innovative preclinical services.